Bariatric surgery is generally safe, but problems after the procedure can occur. It is not clear if patients with hypothyroidism have higher chances of complications after bariatric surgery. This study was done to find out the risks of bariatric surgery in patients with hypothyroidism.
Background: Heterozygosity of genetically encoded misfolded mutant thyroglobulin (TG, the thyroid hormone protein precursor) occurs with a frequency estimated at 1-in-217 people worldwide, resulting in subclinical hypothyroidism that largely escapes medical detection. However, patients carrying biallelic TG mutation, when untreated, are frankly hypothyroid unless and until they develop a massive goiter. To date, TG is the only proven endogenous precursor protein for thyroid hormone synthesis in vertebrates.
A significant change in the 2025 thyroid cancer guidelines is an increase in the recommendation of lobectomy. Prior guidelines indicate that completion thyroidectomy is considered in up to 20% of patients with a lobectomy and cancer >2 and ≤4 cm. This paper summarizes the changes in recommendations for completion thyroidectomy in the 2025 ATA differentiated thyroid cancer guidelines.
Who is eligible for TAE and who is not? How does it compare with surgery, radioactive iodine, or thermal ablation? What should we be telling our patients about expectations, safety, and follow-up after TAE procedures?
All Thyroid® articles are free to read through the end of March as we transition to the new Sage Journals.
This podcast was created in partnership with the American Thyroid Association to discuss up-to-date diagnosis and management of a wide array of thyroid diseases.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.© 2026 American Thyroid Association.
